SCGB1A1 and chronic obstructive pulmonary disease: CC16 has been studied as a possible biomarker of lung epithelial damage in several kinds of diseases including ARDS, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, asthma, and sarcoidosis [22,23].